Abbott Pays $670 Million to Settle Formula Claims as Legal Risks Persist

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

Abbott Laboratories agreed to pay $670 million to settle around 2,000 lawsuits, including the Gill case, which accused the company of distributing infant formulas linked to necrotizing enterocolitis (NEC) in preterm babies. Abbott denies liability, stating the settlements are a compromise of disputed claims. The company faces additional pending lawsuits and scrutiny over heavy metals in its products.

FSSAI issued 150 notices to food companies, including Nestle India, PepsiCo, and Coca-Cola India, for misleading ads, false claims, and labeling violations. The regulator also took action against e-commerce platforms and food service establishments, suspending five Domino's licenses and canceling one Amazon warehouse license.

Abbott Laboratories (ABT) agreed to pay $670 million to settle around 2,000 lawsuits related to its premature infant formulas, including a $495 million verdict. The company denies wrongdoing but aims to resolve broader litigation. Abbott faces additional lawsuits, with a Chicago federal judge overseeing over 825 cases. Analysts suggest this settlement may set a precedent for future cases.

Abbott Laboratories settled around 2,000 legal cases related to its infant formula, paying approximately $670 million. The settlements include a $500 million award to the Gill family for brain damage claims. Abbott denies liability but aims to resolve disputes and reduce future costs. The company faces additional pending lawsuits involving NEC claims.

Abbott Laboratories will pay $670 million to settle lawsuits alleging its preterm infant formula causes necrotizing enterocolitis. The settlement follows a $495 million judgment upheld by an appeals court. Abbott denies liability and faces 1,700 ongoing lawsuits involving 12,700 infants. The company maintains its products are safe.